Prevalence and incidence of Alzheimer's disease in Europe: a meta-analysis by Niu, Hao et al.
Neurología. 2017;32(8):523—532
NEUROLOGÍA
www.elsevier.es/neurologia
ORIGINAL ARTICLE
Prevalence  and incidence  of  Alzheimer’s  disease  in
Europe: A meta-analysis,
H. Niua,∗, I. Álvarez-Álvareza, F. Guillén-Grimaa,b,c, I. Aguinaga-Ontosoa
a Departamento  de  Ciencias  de  la  Salud,  Universidad  Pública  de  Navarra,  Pamplona,  Navarra,  Spain
b Instituto  de  Investigación  Sanitaria  de  Navarra  (IDISNA),  Pamplona,  Navarra,  Spain
c Medicina  Preventiva,  Clínica  Universidad  de  Navarra,  Pamplona,  Navarra,  Spain
Received  14  August  2015;  accepted  27  February  2016
Available  online  23  August  2017
KEYWORDS
Alzheimer’s  disease;
Epidemiology;
Prevalence;
Incidence;
Europe;
Meta-analysis
Abstract
Background:  A  disease  of  unknown  aetiology,  Alzheimer’s  disease  (AD)  is  the  most  common
type of  dementia.  As  the  elderly  population  grows  worldwide,  the  number  of  patients  with  AD
also increases  rapidly.  The  aim  of  this  meta-analysis  is  to  evaluate  the  prevalence  and  incidence
of AD  in  Europe.
Methodology:  We  conducted  a  literature  search  on  Medline,  Scopus,  and  CINAHL  Com-
plete using  the  keywords  ‘‘Alzheimer’’,  ‘‘Alzheimer’s  disease’’,  and  ‘‘AD’’  combined  with
‘‘prevalence’’,  ‘‘incidence’’,  and  ‘‘epidemiology’’.  A  Bayesian  random  effects  model  with  95%
credible  intervals  was  used.  The  I2 statistic  was  applied  to  assess  heterogeneity.
Results:  The  prevalence  of  Alzheimer’s  disease  in  Europe  was  estimated  at  5.05%  (95%  CI,
4.73-5.39).  The  prevalence  in  men  was  3.31%  (95%  CI,  2.85-3.80)  and  in  women,  7.13%  (95%  CI,
6.56-7.72),  and  increased  with  age.
The  incidence  of  Alzheimer’s  disease  in  Europe  was  11.08  per  1000  person-years  (95%  CI,
10.30-11.89).  Broken  down  by  sex,  it  was  7.02  per  1000  person-years  (95%  CI,  6.06-8.05)  in  men
and 13.25  per  1000  person-years  (95%  CI,  12.05-14.51)  in  women;  again  these  rates  increased
with age.
Conclusions:  The  results  of  our  meta-analysis  allow  a  better  grasp  of  the  impact  of  this  disease
in Europe.
e  Neurolog´ıa.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an  open© 2015  Sociedad  Espan˜ola  d
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Prevalencia  e  incidencia  de  la  enfermedad  de  Alzheimer  en  Europa:  metaanálisis
Resumen
Introducción:  La  enfermedad  de  Alzheimer  es  el  principal  tipo  de  demencia  y  una  enfermedad
de etiología  desconocida.  Con  el  aumento  de  la  población  anciana  mundial,  el  número  de
pacientes con  enfermedad  de  Alzheimer  muestra  una  tendencia  de  crecimiento  rápido.  El  obje-
tivo de  este  metaanálisis  es  evaluar  la  prevalencia  e  incidencia  de  la  enfermedad  de  Alzheimer
en Europa.
Metodología:  La  búsqueda  de  artículos  se  realizó  en  las  bases  de  datos  Medline,  Scopus  y
CINAHL Complete  utilizando  las  palabras  claves  «Alzheimer»,  «Alzheimer’s  disease» y  «AD»,
combinadas  con  «prevalence»,  «incidence» y  «epidemiology».  Se  utilizó  el  modelo  bayesiano  de
efectos aleatorios,  mostrando  intervalos  de  credibilidad  del  95%.  Para  estimar  la  heterogeneidad
se usó  el  estadístico  I2.
Resultados:  La  prevalencia  de  enfermedad  de  Alzheimer  en  Europa  fue  5,05%  (IC  del  95%,  4,73-
5,39). La  prevalencia  por  sexo  en  los  hombres  y  las  mujeres  fue  3,31%  (IC  del  95%,  2,85-3,80)
y 7,13%  (IC  del  95%,  6,56-7,72),  respectivamente,  y  se  encontró  una  tendencia  creciente  por
grupos de  edad.
La  incidencia  de  enfermedad  de  Alzheimer  en  Europa  fue  11,08  por  1.000  personas-an˜o  (IC
del 95%,  10,30-11,89),  siendo  en  los  hombres  y  las  mujeres  de  7,02  por  1.000  personas-an˜o  (IC
del 95%,  6,06-8,05)  y  13,25  por  1.000  personas-an˜o  (IC  del  95%,  12,05-14,51),  respectivamente,
con igual  tendencia  creciente  con  el  aumento  de  la  edad.
Conclusiones:  Los  resultados  del  metaanálisis  permiten  una  mejor  comprensión  de  la  enfer-
medad y  su  impacto  en  Europa.
© 2015  Sociedad  Espan˜ola  de  Neurolog´ıa.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este  es  un
art´ıculo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Data  extraction
Data  were  extracted  by  2  researchers  (H.N.  and  I.A.A.)  andntroduction
he  World  Health  Organization  deﬁnes  Alzheimer  disease
AD)  as  a  neurodegenerative  disease  of  unknown  aetiol-
gy,  characterised  by  progressive  memory  and  cognitive
mpairment1 which  accounts  for  50%  to  75%  of  all  cases
f  dementia.2 According  to  global  statistical  data  from  the
lobal  Burden  of  Disease  Study,  AD  was  one  of  the  fastest-
ising  diseases  among  the  leading  50  causes  of  global  years
f  life  lost  between  1990  and  2013.3
Multiple  risk  factors  have  been  identiﬁed,  including
emale  sex,4 age,5 low  education  level,5,6 the  APOE*E4
llele,7,8 smoking,9 obesity,10,11 and  diabetes  mellitus.12
A  collaborative  study  including  the  results  of  several
uropean  population-based  cohorts  conducted  in  the  1990s
ound  a  prevalence  of  4.4%  in  people  older  than  65.13 Rapid
opulation  ageing  has  resulted  in  an  increasing  number  of
atients  with  AD.  In  2006,  a  total  of  26.6  million  patients
ad  AD  worldwide,  with  forecasts  suggesting  that  this  num-
er  will  reach  106.8  million  by  2050,  with  16.51  million
atients  in  Europe.14 More  recent  studies  have  conﬁrmed
his  upward  trend  in  the  incidence  of  dementia,  predicting
 87%  increase  in  Europe  for  the  2010-2050  period.15
A  deeper  understanding  of  the  epidemiology  of  AD  is
herefore  important  for  early  prevention,  as  it  helps  health-
are  authorities  and  reduces  the  impact  of  the  disease  on
he  elderly.  This  meta-analysis  aims  to  analyse  the  available
iterature  and  estimate  the  prevalence  and  incidence  of  AD
n  Europe.
daterial and methods
earch  strategy  and  selection  criteria
e  searched  the  MEDLINE,  SCOPUS,  and  CINAHL  Complete
atabases  for  articles  published  between  1  January  1995
nd  31  March  2015  and  written  in  English,  Spanish,  French,
talian,  or  Portuguese.
We  searched  by  title  using  the  following  keywords:
‘Alzheimer’’,  ‘‘Alzheimer’s  disease’’,  and  ‘‘AD’’,  combined
ith  ‘‘prevalence’’,  ‘‘incidence’’,  and  ‘‘epidemiology’’.
 total  of  615  articles  were  gathered.  Additionally,  we
eviewed  the  references  cited  by  the  selected  articles  to
dentify  additional  studies  meeting  our  inclusion  criteria.
wo  researchers  (H.N.  and  I.A.A.)  searched  for  and  assessed
he  articles;  any  discrepancies  were  solved  by  consensus.
Our  meta-analysis  included  all  observational  studies  ful-
lling  the  following  criteria:  1)  original  articles;  2)  including
uropean  populations;  3)  participants  were  men  and  women
lder  than  50;  4)  providing  original  data  on  prevalence
nd/or  incidence;  5)  describing  diagnosis  of  AD,  and  6)  avail-
ble  in  full  text.  Review  articles,  meta-analyses,  and  studies
ot  addressing  the  epidemiology  of  AD  were  excluded.iscrepancies  were  resolved  through  consultation  with  a
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134 studies found 
in MEDLINE
197 studies found
 in Scopus
615 total studies
149 studies were further 
analysed
44 studies were further analysed
105 studies whose population
 was not European
15 duplicated studies
8 review studies
11 studies with no useful data
1 study with a different methodology
466 studies did not meet 
the selection criteria
9 studies cited in references
18 studies included in the meta-analysis
104 studies found in 
CINAHL 
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eFigure  1  Flow  chart  displa
third  researcher  (F.G.G.).  The  meta-analysis  included  the
following  data  from  each  article:  1)  surname  of  the  ﬁrst
author,  year  of  publication,  country  of  the  study  population;
2)  demographic  characteristics  (number  of  participants,  age
range);  3)  mean  follow-up  time;  4)  number  of  patients  with
AD  used  to  calculate  the  prevalence;  5)  patients  with  AD  and
person-years  at  risk  used  to  calculate  the  incidence.
Quantitative  analysis  (meta-analysis)
Separate  meta-analyses  were  conducted  for  prevalence
and  incidence.  We  used  Fast*Pro  software  and  a  Bayesian
random-effects  model  with  a  95%  credible  interval  (95%  CI).
Bayesian  credible  intervals  are  different  from  frequentist
conﬁdence  intervals:  a  95%  credible  interval  indicates  that
the  probability  that  the  true  value  lies  within  the  interval  is
95%  according  to  the  data  observed  and  prior  belief,  whereas
a  95%  conﬁdence  interval  indicates  that  95%  of  the  inter-
vals  would  include  the  true  value  if  numerous  samples  were
taken.  We  conducted  sensitivity  analyses,  replicating  the
results  after  excluding  one  study  to  examine  the  robustness
of  the  analysis  and  the  inﬂuence  of  the  excluded  study.
Heterogeneity  was  assessed  with  I2,  a  statistic  that  esti-
mates  the  percentage  of  total  variation  due  to  heterogeneity
across  studies.16
a
l
w
wthe  study  selection  process.
Brayne  et  al.19 and  Andersen  et  al.27 used  patient  and
erson-years  data  from  patients  with  minimal  and  greater
everity  AD,  and  very  mild  to  severe  AD,  respectively.  The
tudy  by  Copeland  et  al.28 calculated  patient  and  person-
ears  at  risk  based  on  data  from  women  and  men  of  all  ages.
e  included  the  study  by  Tsolaki  et  al.26 in  the  meta-analyses
f  the  prevalence  and  incidence  of  AD.
esults
he  MEDLINE  search  yielded  314  articles;  239  articles  were
xcluded  for  not  meeting  the  selection  criteria  and  the
emaining  75  articles  required  further  analysis.  Of  these,
8  were  excluded  because  they  did  not  include  European
opulations.  Of  the  remaining  27  studies,  we  excluded  7
eview  articles,  11  articles  whose  data  were  not  useful,
nd  one  study  with  a  different  research  methodology.  Our
eta-analysis  included  8  articles  from  MEDLINE.
We  found  197  articles  in  Scopus;  143  of  these  were
xcluded  for  not  fulﬁlling  the  selection  criteria,  and  an
dditional  39  articles  were  excluded  because  their  popu-
ations  were  not  European.  Of  the  remaining  15  studies,
e  excluded  one  review  article,  4  articles  whose  data
ere  not  useful,  and  one  study  with  a  different  research
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Table  1  Characteristics  of  the  included  studies.
Study  Population  Screening  test  Diagnostic  criteria  for
dementia/AD
Neuropathological
conﬁrmation
Letenneur  et  al.17
(1994,  France)
Com  MMSE,  BVRT,
WPA
DSM-III-R/NINCDS-ADRDA  Yes
Manubens et  al.18
(1995,  Spain)
Com/Ins  CAMDEX  DSM-III-R/NINCDS-ADRDA  No
Brayne et  al.19 (1995,
United  Kingdom)
Com  MMSE  CAMDEX  No
Ott et  al.20 (1995,  the
Netherlands)
Com/Ins  MMSE,  GMS  DSM-III-R/NINCDS-ADRDA  Yes
Prencipe et  al.21
(1996,  Italy)
Com  MMSE,  MSQ DSM-III/NINCDS-ADRDA  Yes
Aevarsson et  al.22
(1996,  Sweden)
Com/Ins  CPRS,  MMSE  DSM-III-R/NINCDS-ADRDA  Yes
Ferini-Strambi  et  al.23
(1997,  Italy)
Com/Ins  AMT  NINDS-AIREN/NINCDS-
ADRDA
No
Obadia et  al.24 (1997,
France)
Com/Ins  MMSE  DSM-III-R/NINCDS-ADRDA  No
Salamon et  al.25
(1999,  France)
Com/Ins  MMSE,  BVRT,
WPA
DSM-III-R/NINCDS-ADRDA  Yes
Tsolaki et  al.26 (1999,
Greece)
Com  MMSE,
CAMDEX
DSM-III-R/NINCDS-ADRDA  Yes
Andersen et  al.27
(1999,  Denmark)
Com/Ins  CAMDEX  DSM-III-R/NINCDS-ADRDA  Yes
Copeland et  al.28
(1999,  United
Kingdom)
Com/Ins  GMS,  MMSE  GMS-AGECAT  Yes
Di Carlo  et  al.29
(2002,  Italy)
Com/Ins  MMSE  DSM-III-R/NINCDS-ADRDA  No
López-Pousa  et  al.30
(2004,  Spain)
Com  MMSE,  RCDI  CAMDEX,  DSM-III-R  No
Ravaglia et  al.31
(2005,  Italy)
Com  GMS,  MMSE  DSM-IV/NINCDS-ADRDA  Yes
Bermejo-Pareja
et al.32 (2008,
Spain)
Com/Ins  MMSE,  FAQ  DSM-IV/NINCDS-ADRDA  No
Lobo et  al.33 (2011,
Spain)
Com  MMSE,  GMS,
HAS
DSM-IV/NINCDS-ADRDA  No
Tola-Arribas  et  al.34
(2013,  Spain)
Com/Ins  7MS,  IQCODE,
KDQ
DSM-IV/NINCDS-ADRDA  Yes
AGECAT: Automated Geriatric Examination for Computer Assisted Taxonomy; AMT: Abbreviated Mental Test; BVRT: Benton Visual Reten-
tion Test; CAMDEX: Cambridge Mental Disorders of the Elderly Examination; Com: community-living patients; CPRS: Comprehensive
Psychopathological Rating Scale; DSM: Diagnostic and Statistical Manual of Mental Disorders; FAQ: Functional Activities Questionnaire;
GDS: Geriatric Depression Scale; GMS: Geriatric Mental State; HAS: History and Aetiology Schedule; Ins: institutionalised patients;
IQCODE: Informant Questionnaire on Cognitive Decline in the Elderly; KDQ: Kawas Dementia Questionnaire; MMSE: Mini—Mental State
Examination; MSQ: Mental Status Questionnaire; NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and
Stroke-Alzheimer’s Disease and Related Disorders Association; NINDS-AIREN: National Institute of Neurological Disorders and Stroke-
Association Internationale pour la Recherche et l’Enseignement en Neurosciences; RCDI: Retrospective Collateral Dementia Interview;
WPA: Wechsler’s Paired-Associates; 7MS: 7-Minute Screen Neurocognitive Battery.
Sources: Folstein et al.,36 Benton,37 Wechsler,38 Roth et al.,39 Copeland et al.,40 Copeland et al.,41 Kahn et al.,42 Asberg et al.,43 Rocca
et al.,44 Davis et al.,45 Yesavage et al.,46 Pfeffer et al.,47 Dewey et al.,48 Solomon et al.,49 Jorm and Korten,50 Kawas et al.,51 American
Psychiatric Association,52 American Psychiatric Association,53 McKhann et al.,54 and Roman et al.55
m
H
e
iethodology.  The  remaining  9  articles  met  all  the  criteria.
owever,  8  of  these  were  duplicated  and  were  therefore
xcluded.  As  a  result,  only  one  article  from  Scopus  was
ncluded  in  our  meta-analysis.
c
i
aThe  CINAHL  Complete  literature  search  yielded  104  arti-
les;  84  of  these  did  not  meet  the  criteria  and  18  did  not
nclude  European  populations.  Two  articles  required  further
nalysis:  one  of  them  was  a  review  article  and  the  other
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Table  2  Meta-analysis  of  prevalence  of  Alzheimer  disease  in  Europe,  broken  down  by  sex  and  age  group.
Type  of  study  Age
range
Patients
with  AD  (n)
Men  Women  65-74
years
75-84  years  ≥85  years  ≤79  years  ≥80  years
Manubens  et  al. 70-91 119  (1019) 41  (562) 78  (565) 1  (146) 52  (613) 66  (368) 24  (457) 95  (670)
Ott et  al. 55-106 339  (7528) 76  (2939) 263  (4589) 24  (2563) 121  (1643) 190  (709) —  —
Prencipe et  al. >64  50  (968) 21  (418) 27  (550) 7  (544) 32  (359) 11  (65) —  —
Ferini-Strambi
et al.
>59  27  (673) 7  (254) 20  (419) —  —  —  11  (573)  16  (100)
Obadia et  al. ≥70 82  (1068) 16  (432) 66  (636) —  —  —  28  (679)  54  (389)
Salamon et  al. ≥65 128  (4123)  —  —  —  —  —  —  —
Tsolaki et  al.  ≥70  20  (365)  4  (159)  16  (206)  2  (118)  12  (206)  6  (41)  10  (230)  10  (135)
Tola-Arribas
et al.
≥65  143  (2170)  26  (933)  117  (1237)  10  (1024)  63  (813)  70  (333)  37  (1473)  106  (697)
Meta-analysis 5.05%
(4.73-5.39)
3.31%
(2.85-3.80)
7.13%
(6.56-7.72)
0.97%
(0.70-1.28)
7.66%
(6.79-8.59)
22.53%
(20.20-
24.08)
3.18%
(2.61-3.81)
14.04%
(12.44-
15.73)
Table  3  Meta-analysis  of  incidence  of  Alzheimer  disease  in  Europe,  broken  down  by  sex  and  age  group  (person-years  at  risk).
Type  of  study  Age
range
Mean  follow-up
time  (years)
Patients  with
AD  (P-Y)
Men  Women  65-74  years  75-84  years  ≥85  years
Letteneur  et  al. ≥65 3  59  (5136.5)  19  (1566.9)  40  (2321.3)  4  (2628.6)  30  (2068.7)  25  (518.3)
Brayne et  al. ≥75 2.4 65  (2361)  19  (855)  46  (1509)  —  44  (2045)  21  (280)
Aevarsson et  al. 85-88 3  27  (699.2)  5  (212.2)  22  (487)  —  —  27  (699.2)
Andersen et  al. 65-84 2.1 102  (4872) —  —  33  (3303)  69  (1569)  —
Copeland et  al. ≥65 4  73  (7287) 23  (3505) 50  (3782)  4  (2664)  12  (2499)  57  (2124)
Tsolaki et  al. ≥70 2  26  (496) 6  (214)  20  (282)  1  (66)  16  (352)  9  (78)
Di Carlo  et  al. 65-84 3.8 67  (9524.8) 25  (5034.7) 42  (4490.1)  19  (5731.7)  48  (3793.1)  —
López-Pousa et  al. ≥75 4.3 52  (4825) 13  (1994)  39  (2838)  —  30  (3739)  22  (1077)
Ravaglia et  al. ≥65 3.8 72  (3044.4) 24  (1421.8) 48  (1622.6)  18  (1595)  33  (1172.2)  21  (277.2)
Bermejo-Pareja et  al. ≥65 3.2 115  (12  552) 35  (5355) 80  (7197) 18  (6452)  55  (4843)  42  (1257)
Lobo et  al. ≥55 4.5 87  (16  025) 26  (7050) 61  (8975) 6  (6690) 19  (3461)  62  (1593)
Meta-analysis 11.08
(10.30-11.89)
7.02
(6.06-8.05)
13.25
(12.05-
14.51)
3.43
(2.79-4.14)
13.78
(12.38-
15.26)
35.74
(31.70-
40.03)
P-Y: person-years at risk.
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DiscussionFigure  2  Prevalence  of  Alzheimer  disease.
ollowed  an  incompatible  methodology.  No  studies  from
INAHL  Complete  were  therefore  included  in  our  meta-
nalysis.
After  reading  the  included  articles,  we  identiﬁed  and
dded  9 new  articles  cited  in  their  reference  lists;  our
eta-analysis  ﬁnally  included  a  total  of  18  original  articles
Fig.  1).  As  an  exception,  we  included  the  study  by  Leten-
17eur  et  al. for  its  importance  as  part  of  the  EURODEM
tudy.35
Study  characteristics  are  listed  in  Table  1.  Our  selec-
ion  of  articles  included  8  observational  cross-sectional
I
lH.  Niu  et  al.
tudies,  which  were  included  in  the  meta-analysis  of  preva-
ence  (Table  2),  and  11  longitudinal  or  cohort  studies,  which
ere  used  for  the  meta-analysis  of  incidence  (Table  3).  The
tudy  by  Tsolaki  et  al.26 was  used  in  both  meta-analyses,
iven  that  it  was  cross-sectional  and  longitudinal.
The  populations  came  from  the  following  countries:
pain,  the  Netherlands,  Italy,  France,  Greece,  United  King-
om,  Sweden,  and  Denmark.  Sample  size  ranged  from  288
o  7528  participants.
Prevalence  of  AD  in  Europe  was  5.05%  (95%  CI,  4.73-5.39)
Fig.  2).  After  conducting  a  sensitivity  analysis  excluding
he  study  by  Manubens  et  al.18, prevalence  was  estimated
t  4.66%  (95%  CI,  4.34-4.99).  Prevalence  of  AD  was  6.88%
95%  CI,  6.19-7.61)  in  southern  European  countries  (Spain,
taly,  and  Greece)  and  4.31%  (95%  CI,  3.26-4.68)  in  northern
uropean  countries  (France,  the  Netherlands).
Prevalence  was  3.31%  (95%  CI,  2.85-3.80)  in  men  and
.13%  (95%  CI,  6.56-7.72)  in  women.
Prevalence  of  AD  increased  with  age:  0.97%,
.66%,  and  22.53%  for  patients  aged  65  to  74  years,
5  to  84  years,  and  85  and  older,  respectively,
nd  3.18%  and  14.04%  for  patients  aged  79  and
ounger  and  those  aged  80  and  older,  respectively
Table  2).
The  heterogeneity  analysis  gave  an  I2 value  of  42.42%,
hich  indicates  moderate  heterogeneity.  After  the  sensitiv-
ty  analysis,  I2 was  6.49%,  indicating  low  heterogeneity;  I2
alues  for  southern  and  northern  European  countries  were
8.9%  and  57.40%,  respectively.
Incidence  of  AD  was  11.08  cases  per  1000  person-years
95%  CI,  10.30-11.89)  (Fig.  3).  Sensitivity  analyses,  which
xcluded  only  the  article  by  Tsolaki  et  al.,26 obtained  an
ncidence  rate  of  10.78  cases  per  1000  person-years  (95%  CI,
0.0-11.58).  After  excluding  only  the  article  by  Aevarsson
t  al.22,  incidence  was  estimated  at  10.80  cases  per  1000
erson-years  (95%  CI,  10.02-11.60).
Incidence  rates  in  southern  European  countries  (Greece,
taly,  and  Spain)  and  northern  European  countries  (France,
nited  Kingdom,  Sweden,  and  Denmark)  were  8.97  cases  per
000  person-years  (95%  CI,  8.13-9.86)  and  15.94  cases  per
000  person-years  (95%  CI,  14.25-17.72),  respectively.
As  with  prevalence,  incidence  of  AD  was  higher  in  women
han  in  men:  13.25  cases  per  1000  person-years  (95%  CI,
2.05-14.51)  vs  7.02  cases  per  1000  person-years  (95%  CI,
.06-8.05).
Incidence  increased  with  age:  3.43,  13.78,  and  35.74
ases  per  1000  person-years  for  patients  aged  65  to  74  years,
5  to  84  years,  and  85  and  older,  respectively  (Table  3).
Heterogeneity  was  found  to  be  high  (I2 =  70.37%).  After
xcluding  the  study  by  Tsolaki  et  al.26 and  the  study  by
evarsson  et  al.22from  the  sensitivity  analysis,  I2 values  were
stimated  at  63.66%  and  68.16%,  respectively.  In  both  cases,
eterogeneity  was  high.  I2 values  for  the  incidence  of  AD  in
outhern  and  northern  European  countries  were  78.80%  and
8.15%,  respectively.mprovements  in  quality  of  life  have  led  to  an  increase  in
ife  expectancy,  which  in  turn  involves  increased  incidence
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f  ageing-related  diseases.  This  meta-analysis  estimated
revalence  and  incidence  rates  of  AD  in  Europe.
Studies  conducted  in  Europe  showed  that  the  age-
tandardised  prevalence  of  AD  was  lower  in  patients  older
han  65  (4.4%),13 whereas  incidence  was  estimated  at  12.33
ases  per  1000  person-years,35 a  higher  rate  than  that  found
n  our  study.  Recent  studies  found  a  signiﬁcant  decrease  in
he  prevalence  of  dementia  in  the  United  Kingdom,56 con-
rary  to  what  we  have  observed  in  our  study.  In  another
tudy,  disease  prevalence  was  found  to  be  stable  and  inci-
ence  displayed  a  non-signiﬁcant  decrease  over  time,  which
s  in  line  with  our  ﬁndings.57
However,  prevention  of  cardiovascular  risk  factors  or
igher  education  levels  may  have  led  to  a  signiﬁcant
ecrease  in  the  incidence  of  dementia  in  recent  years.58
Our  study  showed  a higher  prevalence  and  incidence  of
D  in  women,  which  is  in  line  with  other  studies  reporting
 higher  risk  of  AD  in  women,59,60 especially  in  those  with
ower  education  levels.61
In  Asia,  a  study  carried  out  in  China  showed  that  preva-
ence  of  AD  was  1.27%  in  patients  aged  65  to  69  years  and
8.54%  in  those  aged  85  to  89  years  for  the  year  2010;  preva-
ence  rates  for  all  age  groups  were  higher  in  2010  than  in
990.  Incidence  of  AD  in  the  population  aged  60  or  older
as  6.25  cases  per  1000  person-years.62
In  Japan,  prevalence  of  AD  in  patients  older  than  65  was
%,63 with  an  incidence  rate  of  5.6  cases  per  1000  person-
ears  in  the  population  older  than  60.64 In  South  Korea,
owever,  prevalence  in  the  population  older  than  65  was
.7%.65
These  ﬁndings  show  that  recent  improvements  in  quality
f  life  and  living  conditions,  especially  in  China  and  South
orea,  have  led  to  population  ageing.  This,  in  turn,  has
esulted  in  an  increase  in  the  prevalence  of  age-related  dis-
ases  such  as  AD,  whose  prevalence  is  expected  to  increase
n  the  future  due  to  lifestyle  and  risk  factors  inﬂuencing
he  development  of  dementia  at  advanced  ages.66 Japan,  on
he  other  hand,  has  an  older  population,  which  may  explain
he  higher  prevalence  of  AD.  The  incidence  rate  is  lower  in
apan,  however,  which  is  probably  due  to  the  adoption  of
ealthy  lifestyle  factors  that  may  have  a  protective  effect
gainst  AD,  such  as  diet.67
In  the  United  States,  prevalence  of  AD  in  people  older
han  70  was  estimated  at  9.51%,68 a  higher  rate  than  that
ound  in  our  study,  whereas  the  incidence  rate  was  14.26
ases  per  1000  person-years.69
The  American  population  is  comparable  to  the  European
opulation  both  in  the  proportion  of  elderly  people  and  in
erms  of  living  conditions;  differences  may  therefore  be
ue  to  differences  in  lifestyle:  some  authors  have  associ-
ted  the  Mediterranean  diet  with  a  lower  risk  of  AD,  for
xample.70,71
Heterogeneity  was  found  to  be  medium  in  the  meta-
nalysis  of  prevalence  and  low  in  the  sensitivity  analysis,
fter  excluding  one  study.  However,  the  heterogeneity  of
ncidence  was  found  to  be  high  and  remained  high  with  slight
hanges  when  we  excluded  some  studies.
One  of  the  strengths  of  this  study  is  its  novelty;  as  far
s  we  know,  no  meta-analyses  have  been  conducted  to  date
n  the  prevalence  and  incidence  of  AD  in  Europe.  Further-
ore,  our  study  provides  surprising  results  with  a  high  level
f  scientiﬁc  evidence.  One  of  our  study’s  main  limitations  is
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230  
he  fact  that  we  did  not  have  access  to  more  databases  and
ere  therefore  unable  to  assess  more  articles.
In  conclusion,  we  observed  a  slight  increase  in  the  preva-
ence  of  AD  in  Europe  in  the  past  few  years  and  a  decrease
n  incidence  rates.  These  results  bring  our  knowledge  of  the
pidemiology  of  AD  in  Europe  up  to  date.  Similar  studies
nd  trend  studies  of  AD  in  other  regions  of  the  world  are
lso  necessary.
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